Table 4.
Adjusted comparison of neurobiological measurements between changes from baseline at 12 weeks after intervention in patients with MCI (n = 16).
| Control group (n = 6) | Intervention group (n = 10) | Between-group difference (95%CI)a | P-value | |||
|---|---|---|---|---|---|---|
| Baseline | Change from baseline at 12 weeks | Baseline | Change from baseline at 12 weeks | |||
| Aβ-40 (pg/ml) | 263.9 (71.0) | −44.8 (23.0) | 247.3 (57.2) | −69.1 (39.6) | −18.7 (−56.8, 19.4) | 0.305 |
| Aβ-42 (pg/ml) | 61.9 (27.2) | 3.5 (48.7) | 44.2 (6.9) | 8.6 (16.6) | 12.6 (−21.4, 46.6) | 0.434 |
| Aβ42/Aβ40 | 0.23 (0.08) | 0.1 (0.2) | 0.19 (0.06) | 0.1 (0.1) | 0.1 (−0.1, 0.3) | 0.470 |
| BDNF (ng/ml) | 159.7 (65.9) | −7.5 (55.2) | 110.9 (39.3) | 41.6 (24.3) | 56.6 (12.8, 100.4) | 0.016 |
| IGF-1 (ng/ml) | 17.2 (9.2) | −4.7 (11.6) | 10.1 (2.1) | 2.7 (5.3) | 9.4 (0.5, 18.2) | 0.040 |
| TNF-a (pg/ml) | 3.7 (1.1) | 1.1 (0.5) | 4.0 (1.3) | 0.7 (0.8) | −0.3 (−1.1, 0.5) | 0.405 |
| IL-6 (pg/ml) | 2.1 (0.3) | 1.0 (0.2) | 2.4 (0.3) | 0.5 (0.2) | −0.4 (−0.6, −0.2) | 0.001 |
| sTREM-2 (pg/ml) | 19.4 (13.3) | −4.9 (18.6) | 11.3 (2.9) | 0.1 (6.6) | 7.9 (−5.4, 21.2) | 0.220 |
a
Controlling for age and sex.
Aβ-40, amyloid β-protein-40; BDNF, brain-derived neurotrophic factor; IGF-1, insulin-like growth factor-1; TNF-α, tumor necrosis factor-alpha; IL-6, Interleukin-6; sTREM2, soluble trigger receptor expressed on myeloid cells 2.